ICI’s Nolvadex
Executive Summary
Tamoxifen for the prevention of breast cancer is well tolerated in women at high risk for developing breast cancer, T.J. Powels, MD, Royal Marsden Hospital concluded in a presentation at the May 22 meeting of the American Society of Clinical Oncology. Because tamoxifen has demonstrated low toxicity, high compliance, and a lipid lowering profile in the 200-women pilot trial, a 10,000-patient multicenter trial is beginning enrollment in the U.K. and should be completed in the next two years, Powles said. Results of the pilot trial will be presented at the June 29 meeting of FDA's Oncologic Drugs Advisory Committee.
You may also be interested in...
Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: